生产企业：Biohaven
Opakalim (BHV-7000) is a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy, with RISE3 trial topline results expected in 2H 2026. SK Biopharmaceuticals obtained an exclusive worldwide license from Biohaven to develop and commercialize it, targeting a US launch as early as 2029.
Opakalim (BHV-7000) is a next-generation, selective Kv7.2/7.3 potassium channel activator in Phase 2/3 development for focal epilepsy, with RISE3 trial topline results expected in 2H 2026. SK Biopharmaceuticals obtained an exclusive worldwide license from Biohaven to develop and commercialize it, targeting a US launch as early as 2029.
Selective activator/opener of Kv7.2/7.3 (KCNQ2/3) heteromeric potassium channels; activates the channels to reduce neuronal excitability through the M-current, a mechanism distinct from GABA receptor modulation.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
